Top Markets
Coin of the day
Vectus Biosystems Limited Vectus Biosystems Limited

Vectus Biosystems Limited

VBS
株式のランク #33546
Vectus Biosystems Limited, an Australian medical research and development firm,... Vectus Biosystems Limited, an Australian medical research and development firm, specializes in devising therapies for fibrotic conditions and hypertension. Its pharmaceutical pipeline addresses ailments affecting the heart, kidneys, liver, and lungs. The company's leading experimental drug, VB0004, aims to counter the degradation of functional tissue resulting from fibrosis, scarring, and elevated blood pressure. Furthermore, Vectus intends to advance treatments for hepatic fibrotic diseases, such as non-alcoholic steatohepatitis, and various pulmonary fibrotic disorders. Beyond its therapeutic endeavors, the company also provides AccuCal and RealCount software, tools engineered to enhance the swiftness and precision of DNA and RNA quantification in laboratory settings. Established in 2005, Vectus Biosystems is headquartered in Rosebery, Australia.
株価
$0.11989842
時価総額
$7.42M
変化(1日)
6.25%
変化(1年)
179.27%
AU
取引 Vectus Biosystems Limited (VBS)

カテゴリー

Vectus Biosystems Limited(VBS)の利益
2026 時点の利益 TTM: 0
Vectus Biosystems Limited の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Vectus Biosystems Limited の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益